In cancer treatment by U.S. focused, MRI is used to keep an eye on temperatures

The first evaluation of a procedure that uses the Transurethral ultrasound therapy MRI-controlled has been revealed to the public, and the results show that this procedure can actually end up being feasible and safe for patients with prostate cancer!

The study stresses that although clinical experience with transrectal high intensity focused ultrasound continues to grow and expand, the fact that there is an inability to measure the temperature distribution in the prostate during treatment occurs has been a major limitation; However, with the ability to control the ultrasonic energy delivered-doing so based on actual temperature-would become much easier to effectively predict the extent of cell death. In addition, the study authors pointed out that Mr Thermometry has served well in the past, and that real-time feedback control of temperature could improve the accuracy of treatment when joint high intensity focused ultrasound to MR imaging.

This idea was put to the test by taking eight men with localized prostate cancer and performing the procedure on them; with the patient in spinal anesthesia and with 1 .5T Mr ultrasound units used, Transurethral treatment was carried out, and this was followed by radical prostatectomy. Although no evaluation of the effectiveness of the treatment was included as part of the study, were resected glands have a look and were compared with measurements of temperature MRI with particular attention to thermal damage model.

According to the findings of the report, all patients tolerated the treatment without any problem, and the uncertainty of observed temperature was minus two degrees Celsius. Along the border of the heat coagulation, the average temperature was just over 52 degrees centigrade, and the thermal dose was 3457, while the study revealed an accuracy of reported targeting right about 3 mm and an average treatment rate of 0.5 mL/min.

In recent years, the number of men with prostate cancer diagnosed low or immediate risk has increased as a result of prostate-specific antigen test, and this highlights the need to treat that will have a lower morbidity rate. with this type of therapy for localized prostate cancer, it is now possible to achieve this-and the hope is that additional studies and tests will prove to be the case and that Transurethral ultrasound therapy MRI subsidiary will soon become a viable solution.